BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38

Benzinga · 3d ago
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.